

Universitätsklinikum Charité der Humboldt-Universität zu Berlin
U30056PCT

Abstract

The present invention relates to the use of a proteasome inhibitor for the manufacture of a medicament for the prevention, onset therapy, acute therapy and/or regression of diseases associated with endothelial dysfunction. The present invention also relates to the use of a proteasome inhibitor as a low-dose treatment.